JPRN-UMIN000009881已完成1 期
Phase I clinical trial of HLA-A*2402 restricted epitope peptide cocktail therapy with S-1 for patients with unresectable advanced metastatic pancreatic cancer. - Phase I clinical trial of HLA-A*2402 restricted epitope peptide cocktail therapy with S-1 for patients with unresectable advanced metastatic pancreatic cancer.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Pregnancy or lactation 2)Patients with the intention of pregnancy. 3)Patients have uncontrollable severe infectional diseases. 4)severe diarrhea. 5)Patients who are treated with steroid or immunotherapy during clinical trial. 6)Patients have uncontrollable multiple cancer. 7)Patients who have non-recovered injury. 8)Patients who have ileus and interstitial lung disiease. 9)Patients whom doctors define as inappropriate.
研究者
相似试验
已完成
1 期
Phase I/II clinical trial of HLA-A24 restricted epitope peptide cocktail therapy with UFT+LV for patients with advanced metastatic colorectal cancer.Advanced metastatic colorectal cancersJPRN-UMIN000007801Kinki University School of Medicine30
招募中
2 期
Phase II clinical study of HLA-A*2402-restricted survivin-derived peptide vaccine therapy for patients with recurrent non-muscle-invasive bladder cancerbladder cancerJPRN-UMIN000005819Sapporo Medical University20
已完成
1 期
Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)Pancreatic CancerNCT00655785Fukushima Medical University17
已完成
1 期
Phase I clinical trial of pan-HLA type personalized peptide vaccine for advanced pediatric malignant glioma patientsAdvanced pediatric malignant glioma patients who are refractory to standard therapiesJPRN-UMIN000000760Department of Immunology, Kurume University School of Medicine10
已完成
1 期
Phase I clinical trial of pan-HLA type personalized peptide vaccine for advanced cancer patientsAdvanced cancer patients who are refractory to standard therapies for cancerJPRN-UMIN000000619Department of Immunology, Kurume University School of Medicine40